Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923509 | 0.92 | CHRM3 (0.51) | CHRM3ACKR3TSHRPPARGCCR5 | |
| SCHEMBL4922645 | 0.92 | CHRM3 (0.50) | CHRM3ACKR3TSHRPPARGCCR5 | |
| SCHEMBL4924956 | 0.91 | TSHR (0.59) | CHRM3ACKR3TSHRPPARGCCR5 | |
| SCHEMBL4924883 | 0.89 | TSHR (0.49) | CHRM3ACKR3TSHRPPARGCCR5 | |
| SCHEMBL4921716 | 0.88 | TSHR (0.55) | ACKR3TSHRPPARGCCR5SMN1; SMN2 | |
| SCHEMBL4927323 | 0.88 | TSHR (0.55) | ACKR3TSHRPPARGCCR5SMN1; SMN2 | |
| SCHEMBL4922824 | 0.87 | TSHR (0.55) | CHRM3ACKR3TSHRPPARGCCR5 | |
| SCHEMBL4921760 | 0.87 | TSHR (0.55) | ACKR3TSHRCHRM4PPARGCCR5 | |
| SCHEMBL4924450 | 0.86 | ACKR3 (0.48) | CHRM3ACKR3PPARGCXCR3 | |
| SCHEMBL4927750 | 0.86 | ACKR3 (0.58) | CHRM3ACKR3TSHRSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | CHRM3 37/4885ACKR3 5/4885TSHR 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.